Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1985 Aug;49(2):378–382. doi: 10.1128/iai.49.2.378-382.1985

Trypanolytic activity, agglutinins, and opsonins in sera from animals refractory to Trypanosoma lewisi.

A Ferrante
PMCID: PMC262026  PMID: 3926649

Abstract

An examination of sera from a range of animals refractory to Trypanosoma lewisi showed that some contain trypanolytic activity and agglutinins for this trypanosome. Trypanolytic activity was demonstrated in bovine, sheep, and rabbit serum. These sera were shown to also contain agglutinins. The trypanolytic activity in all three sera was abolished by heat inactivation at 56 degrees C for 30 min. Studies with bovine serum showed that the lytic activity was totally inhibited by the addition of EDTA but was only partially inhibited by ethylene glycol-bis(beta-aminoethyl ether)-N,N-tetraacetic acid-Mg2+, suggesting the involvement of both classical and alternate pathways of complement activation. Serum from the natural host, the rat but not mouse serum, was capable of inhibiting the trypanolytic activity of bovine serum. The agglutinins in bovine serum were specific, since they could be adsorbed out with T. lewisi but not T. musculi. They fractionated on gel filtration in the position expected for 19S antibodies. By using opsonization measuring techniques, it was found that mouse serum lacked opsonins to T. lewisi, although opsonic activity was detectable in human serum. The absence of agglutinins, trypanolysins, and opsonins in mouse serum suggests that other factors prevent the infection of mice by T. lewisi. From these findings, it would appear that the inability of T. lewisi to infect a range of mammals, with the exception of mice, could be due to the presence of antibodies, the ability to activate complement through the alternative pathway, or both. The absence of these recognition factors and the ability to evade the effects of alternative pathway activation may be important factors in the ability of this parasite to establish infections in rats.

Full text

PDF
378

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albright J. W., Albright J. F. Basis of the specificity of rodent trypanosomes for their natural hosts. Infect Immun. 1981 Aug;33(2):355–363. doi: 10.1128/iai.33.2.355-363.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Budzko D. B., Pizzimenti M. C., Kierszenbaum F. Effects of complement depletion in experimental chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi. Infect Immun. 1975 Jan;11(1):86–91. doi: 10.1128/iai.11.1.86-91.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dwyer D. M. Immunologic and fine structure evidence of avidly bound host serum proteins in the surface coat of a bloodstream trypanosome. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1222–1226. doi: 10.1073/pnas.73.4.1222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Easmon C. S., Cole P. J., Williams A. J., Hastings M. The measurement of opsonic and phagocytic function by Luminol-dependent chemiluminescence. Immunology. 1980 Sep;41(1):67–74. [PMC free article] [PubMed] [Google Scholar]
  5. Ferrante A., Allison A. C. Alternative pathway activation of complement by African trypanosomes lacking a glycoprotein coat. Parasite Immunol. 1983 Sep;5(5):491–498. doi: 10.1111/j.1365-3024.1983.tb00763.x. [DOI] [PubMed] [Google Scholar]
  6. Ferrante A., Allison A. C., Hirumi H. Polyamine oxidase-mediated killing of African trypanosomes. Parasite Immunol. 1982 Sep;4(5):349–354. doi: 10.1111/j.1365-3024.1982.tb00446.x. [DOI] [PubMed] [Google Scholar]
  7. Ferrante A., Allison A. C. Natural agglutinins to African trypanosomes. Parasite Immunol. 1983 Nov;5(6):539–546. doi: 10.1111/j.1365-3024.1983.tb00770.x. [DOI] [PubMed] [Google Scholar]
  8. Ferrante A., Jenkin C. R. Evidence implicating the mononuclear phagocytic system of the rat in immunity to infections with Trypanosoma lewisi. Aust J Exp Biol Med Sci. 1978 Apr;56(2):201–209. doi: 10.1038/icb.1978.22. [DOI] [PubMed] [Google Scholar]
  9. Ferrante A., Jenkin C. R. Surface immunoglobulins, a possible mechanism for the persistence of Trypanosoma lewisi in the circulation of rats. Aust J Exp Biol Med Sci. 1977 Jun;55(3):275–280. doi: 10.1038/icb.1977.22. [DOI] [PubMed] [Google Scholar]
  10. Ferrante A. The role of natural agglutinins and trypanolytic activity in host specificity of Trypanosoma musculi. Parasite Immunol. 1984 Nov;6(6):509–517. doi: 10.1111/j.1365-3024.1984.tb00821.x. [DOI] [PubMed] [Google Scholar]
  11. Ferrante A., Thong Y. H. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods. 1978;24(3-4):389–393. doi: 10.1016/0022-1759(78)90143-6. [DOI] [PubMed] [Google Scholar]
  12. Ferrante A., Thong Y. H. Separation of mononuclear and polymorphonuclear leucocytes from human blood by the one-step Hypaque-Ficoll method is dependent on blood column height. J Immunol Methods. 1982;48(1):81–85. doi: 10.1016/0022-1759(82)90212-5. [DOI] [PubMed] [Google Scholar]
  13. Fine D. P., Marney S. R., Jr, Colley D. G., Sergent J. S., Des Prez R. M. C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972 Oct;109(4):807–809. [PubMed] [Google Scholar]
  14. Greenblatt C. L., Shelton E. Mouse serum as an environment for the growth of Trypanosoma lewisi. Exp Parasitol. 1968 Apr;22(2):187–200. doi: 10.1016/0014-4894(68)90091-x. [DOI] [PubMed] [Google Scholar]
  15. Kipnis T. L., David J. R., Alper C. A., Sher A., da Silva W. D. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A. 1981 Jan;78(1):602–605. doi: 10.1073/pnas.78.1.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Krettli A. U., Weisz-Carrington P., Nussenzweig R. S. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol. 1979 Sep;37(3):416–423. [PMC free article] [PubMed] [Google Scholar]
  17. LINCICOME D. R. Growth of Trypanosoma lewisi in the heterologous mouse host. Exp Parasitol. 1958 Jan;7(1):1–13. doi: 10.1016/0014-4894(58)90002-x. [DOI] [PubMed] [Google Scholar]
  18. Nielsen K., Sheppard J., Tizard I., Holmes W. Trypanosoma lewisi: characterization of complement-activating components. Exp Parasitol. 1977 Oct;43(1):153–160. doi: 10.1016/0014-4894(77)90018-2. [DOI] [PubMed] [Google Scholar]
  19. Rifkin M. R. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3450–3454. doi: 10.1073/pnas.75.7.3450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sheppard J., Nielsen K., Tizard I., Holmes W. Direct activation of complement by trypanosomes. J Parasitol. 1978 Jun;64(3):544–546. [PubMed] [Google Scholar]
  21. Sturtevant J. E., Balber A. E. Externally disposed membrane polypeptides of intact and protease-treated Trypanosoma lewisi correlated with sensitivity to alternate complement pathway-mediated lysis. Infect Immun. 1983 Dec;42(3):869–875. doi: 10.1128/iai.42.3.869-875.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES